Company · CIK 0001520262 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Alkermes plc. · ALKS
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 SForm 4 → | Sep 3, 6:32 pm EDT | David Joseph GaffinEVP, CLO, Alkermes, Inc. | 2,034 | $48.01 | $97,652 | 223,422 | −0.90% | 10b5-1 |
| Sep 1, 2026 SForm 4 → | Sep 1, 7:08 pm EDT | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 9,000 | $46.99 | $422,874 | 65,389 | −12.1% | 10b5-1 |
| Sep 1, 2026 MForm 4 → | Sep 1, 7:08 pm EDT | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 5,000 | $24.59 | $122,950 | 74,389 | — | 10b5-1 |
| Aug 17, 2026 SForm 4 → | Aug 17, 6:53 pm EDT | Christian Todd NicholsSVP, Chief Commercial Officer | 7,576 | $49.23 | $372,937 | 102,193 | −6.90% | 10b5-1 |
| Aug 3, 2026 SForm 4 → | Aug 3, 7:16 pm EDT | nancy lynn snyderman M.D.Director | 44,472 | $50.35 | $2,239,076 | 15,395 | −74.3% | |
| Aug 3, 2026 MForm 4 → | Aug 3, 7:16 pm EDT | nancy lynn snyderman M.D.Director | 44,472 | $46.72 | $2,077,732 | 59,867 | — | |
| Aug 3, 2026 SForm 4 → | Aug 3, 7:12 pm EDT | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 9,000 | $48.58 | $437,220 | 69,389 | −11.5% | 10b5-1 |
| Aug 3, 2026 MForm 4 → | Aug 3, 7:12 pm EDT | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 5,000 | $24.48 | $122,404 | 78,389 | — | 10b5-1 |
| Aug 3, 2026 SForm 4 → | Aug 3, 7:09 pm EDT | David Joseph GaffinEVP, CLO, Alkermes, Inc. | 2,034 | $48.58 | $98,812 | 225,456 | −0.89% | 10b5-1 |
| Jul 6, 2026 SForm 4 → | Jul 6, 4:48 pm EDT | David Joseph GaffinEVP, CLO, Alkermes, Inc. | 2,034 | $54.03 | $109,897 | 227,490 | −0.89% | 10b5-1 |
| Jul 1, 2026 SForm 4 → | Jul 1, 6:29 pm EDT | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 9,000 | $51.51 | $463,621 | 73,389 | −10.9% | 10b5-1 |
| Jul 1, 2026 MForm 4 → | Jul 1, 6:29 pm EDT | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 5,000 | $19.34 | $96,700 | 82,389 | — | 10b5-1 |
| Jun 12, 2026 SForm 4 → | Jun 12, 8:04 pm EDT | Christopher I WrightDirector | 2,000 | $45.10 | $90,200 | 25,680 | −7.23% | 10b5-1 |
| Jun 4, 2026 SForm 4 → | Jun 4, 5:00 pm EDT | David Joseph GaffinEVP, CLO, Alkermes, Inc. | 2,034 | $43.05 | $87,564 | 229,524 | −0.88% | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 MForm 4 → | Sep 1, 7:08 pm EDT | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 5,000 | — | — | 61,276 | — | 10b5-1 |
| Aug 5, 2026 AForm 4 → | Aug 7, 9:17 pm EDT | Blair Curtis JacksonPresident & CEO, Alkermes plc, Director | 217,534 | — | — | 124,305 | — | |
| Aug 3, 2026 MForm 4 → | Aug 3, 7:16 pm EDT | nancy lynn snyderman M.D.Director | 44,472 | — | — | 0 | — | |
| Aug 3, 2026 MForm 4 → | Aug 3, 7:12 pm EDT | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 5,000 | — | — | 66,276 | — | 10b5-1 |
| Jul 1, 2026 MForm 4 → | Jul 1, 6:29 pm EDT | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 5,000 | — | — | 1,356 | — | 10b5-1 |